OverviewSuggest Edit

CollPlant is a regenerative medicine company focused on 3D bioprinting of tissues and organs, and on developing and commercializing tissue repair products for orthobiologics, and advanced wound care markets. The Company's rhCollagen BioInk product line is used for 3D bioprinting of tissues and organs, and a Vergenix line of rhCollagen products includes a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote an optimal healing of acute and chronic wounds.

TypePublic
Founded1981
HQRehovot, IL
Websitecollplant.com

Latest Updates

Employees (est.) (Mar 2018)39
Share Price (Sept 2020)$7.8
Cybersecurity ratingBMore

Key People/Management at CollPlant

Yehiel Tal

Yehiel Tal

Chief Executive Officer
Abraham Havron

Abraham Havron

Director
Oded Shoseyov

Oded Shoseyov

Founder and Chief Scientist
Gili Hart

Gili Hart

Director
Eran Rotem

Eran Rotem

Deputy CEO & Chief Financial Officer
Nadav Orr

Nadav Orr

Vice President, Research and Development
Show more

CollPlant Office Locations

CollPlant has offices in Rehovot and New York
Rehovot, IL (HQ)
Prof. Hillel ve-Khanan Oppenheimer St 4
New York, US
1270 6th Ave 7th fl
Show all (2)

CollPlant Financials and Metrics

CollPlant Revenue

Market capitalization (25-Sept-2020)

50.2m

Closing stock price (25-Sept-2020)

7.8
CollPlant's current market capitalization is $50.2 m.
Show all financial metrics

CollPlant Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

CollPlant Online and Social Media Presence

Embed Graph

CollPlant News and Updates

CollPlant and United Therapeutics Announce Exercise of Option that will Expand their Collaboration to Include 3D Bioprinting of Human Kidneys for Transplant

REHOVOT, Israel and SILVER SPRING, Maryland, Sept. 21, 2020 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) and United Therapeutics Corporation (NASDAQ: UTHR) today announced an expansion of their collaboration with the exercise by United Therapeutics of its option to cover a...

CollPlant Biotechnologies Reports Second Quarter (Q2) 2020 Financial Results

REHOVOT, Israel, Aug. 28, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the second quarter ended June 30, 2020 and provided an update on the Company's business developments. Certain metrics, including...

CollPlant Biotechnologies Reports Year End Financial Results for Fiscal Year 2019

REHOVOT, Israel, April 1, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetics medicine company, today announced financial results for the full year ended December 31, 2019 and provided an update on the Company's business developments. Certain metrics, including...

CollPlant Launches New Corporate Website to Showcase Recent Developments in Core Business Segments

REHOVOT, Israel, Feb. 4, 2020 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, today announced the launch of its updated corporate website. The new website has a clean uncluttered design, improved functionality and enhanced rich content focused on...

3D Bioprinting Industry Study, 2019-2025 - Leading Players are Organovo Holdings, 3D Systems, CELLINK, Stratasys, and CollPlant

DUBLIN, Jan. 10, 2020 /PRNewswire/ -- The "Global 3D Bioprinting Market 2019-2025" report has been added to ResearchAndMarkets.com's offering. The global 3D bioprinting market is anticipated to grow at a significant rate during the forecast period. The major factors contributing to the...

CollPlant Reports Third Quarter 2019 Financial Results and Provides Business Update

REHOVOT, Israel, Nov. 29, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced financial results for the third quarter ended September 30, 2019 and provided an update on the Company's business developments. Certain metrics, including those...
Show more

CollPlant Frequently Asked Questions

  • When was CollPlant founded?

    CollPlant was founded in 1981.

  • Who are CollPlant key executives?

    CollPlant's key executives are Yehiel Tal, Abraham Havron and Oded Shoseyov.

  • How many employees does CollPlant have?

    CollPlant has 39 employees.

  • Who are CollPlant competitors?

    Competitors of CollPlant include PLUS THERAPEUTICS, Pharmanutra and Delcath Systems.

  • Where is CollPlant headquarters?

    CollPlant headquarters is located at Prof. Hillel ve-Khanan Oppenheimer St 4, Rehovot.

  • Where are CollPlant offices?

    CollPlant has offices in Rehovot and New York.

  • How many offices does CollPlant have?

    CollPlant has 2 offices.